Funding for this research was provided by:
National Institute of Mental (ZIAMH002927)
National Institutes of Health
Received: 12 October 2021
Accepted: 30 May 2022
First Online: 1 July 2022
: The STEP-BD study was conducted across 22 academic medical centers in the United States and was approved by the institutional review board of the participating institutions. All participants provided written informed consent.
: As part of the informed consent process, participants in the STEP-BD study provided consent for their anonymized data to be published.
: Dr. Zarate is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2<i>R</i>,6<i>R</i>)-hydroxynorketamine, (<i>S</i>)-dehydronorketamine, and other stereoisomeric dehydroxylated and hydroxylated metabolites of (<i>R,S</i>)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2<i>R</i>,6<i>R</i>)-hydroxynorketamine and (2<i>S</i>,6<i>S</i>)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. All other authors have no conflict of interest to disclose, financial or otherwise.